Latest news

Adalvo is pleased to announce that it has entered into a partnership with Juno Pharmaceuticals Canada, to commercialize a number of respiratory and dermatology dossiers. This licensing and supply agreement includes a basket...

Adalvo is pleased to announce the successful DCP submission for Bosutinib 100, 400, 500mg film-coated tablets, indicated for the treatment of Chronic Myelogenous Leukemia. In 2022, this product achieved global sales...

Adalvo are pleased to announce the successful DCP submission for Afatinib 20, 30, 40, 50mg film-coated tablets. Based on the reference brand, GIOTRIF, Afatinib is indicated for the treatment of metastatic non-small cell...

On this World Diabetes Day, Adalvo showcases the strides made in the realm of diabetic care. Rooted in our commitment to patient well-being, Adalvo stands as one of the leading B2B...

We are pleased to announce our successful DCP submission for Riociguat tablets. Based on the reference brand, Adempas, Riociguat is indicated for the treatment of adult patients with WHO Functional Class (FC) II...

Adalvo, in collaboration with Arphio, is proud to introduce Teduglutide, a groundbreaking treatment addressing the urgent unmet needs of patients with Short Bowel Syndrome (SBS).

Adalvo is excited to remind you that CPhI Barcelona 2023 is just one week away! From October 24th to 26th, we will be part of this exceptional pharmaceutical event, and we've got...

Adalvo and Eurolab are pleased to announce the extension of their long-term strategic collaboration, signing a basket deal for three more products to be marketed and distributed in South Africa and as well as certain SSA...

Adalvo is committed to delivering diversified and competitive assets, supporting our partners in every step of their journey. This is what positions Adalvo for success. We are pleased to announce the successful...

Adalvo is pleased to announce that the successful Pivotal BE Study for Bosutinib Film Coated Tablets has been completed, and we are currently preparing for our DCP submission, scheduled for November 2023. This product is used...

Adalvo is thrilled to be making remarkable strides in the world of diabetic care. With an unwavering commitment to patient well-being, Adalvo proudly stands alone as the sole B2B company...

Adalvo proudly joins the global initiative to raise awareness on heart health, as the world marks World Heart Day on Friday, September 29th. Adalvo is deeply committed to cardiovascular health, and...

Adalvo are honored to have been recognized by CPhI Pharma, where our CEO, Anil Okay, has been nominated as a finalist for the CEO of the Year Award! The CPhI...

Who says pharma events have to be all work and no play? Join us for an enjoyable break during CPhI 2023 on Wednesday, October 25th, starting at 16:00. Come socialize with Adalvo's bees and, if...

Adalvo is excited to announce the launch of Gabapentin ER 300/600 mg in South Korea, in collaboration with our sister company, Lotus. Our product is based on the reference...

Adalvo proudly acknowledges September as Pain Awareness Month, joining the global community in raising awareness about the challenges faced by individuals dealing with chronic pain. With a strong commitment to improving the...

We are pleased to announce our successful DCP submission for Empagliflozin 25mg film-coated tablets, which was developed in collaboration with one of our strategic partners. Our product has been developed...

Adalvo Ltd. (Adalvo) and Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced a collaboration agreement for Rifamycin SV with MMX® technology in Europe, Asia-Pacific (APAC), Middle East/North Africa (MENA) and Latin America (LATAM) regions. Under...

Adalvo is pleased to announce a new collaboration with Eurofarma, a Brazilian-owned multinational pharmaceutical company that promotes access to health and quality of life with treatments at a fair price and profitable operations. This collaboration...